Danger of systemic cyclosporine for corneal graft.
Cornea
; 21(6): 613-4, 2002 Aug.
Article
em En
| MEDLINE
| ID: mdl-12131043
ABSTRACT
PURPOSE:
To report a case of posttransplant lymphoproliferative disorder (PTLD) in a patient receiving oral cyclosporine (CS) for immunosuppression in a high-risk keratoplasty.METHODS:
A systemic CS therapy was given to prevent graft rejection of a keratoplasty. Risk rejection was high in regard to a previous graft rejection and persistence of a corneal vascularization. One year after the keratoplasty, the patient developed a gastric Epstein-Barr virus (EBV)-induced B cell lymphoma. The outcome was favorable after chemotherapy.CONCLUSIONS:
This unique case of lymphoma (PTLD) in the course of corneal graft management questions the indications and the follow-up of patients with CS therapy and raises the issue of topical CS treatment.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Linfoma de Células B
/
Ceratoplastia Penetrante
/
Ciclosporina
/
Imunossupressores
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Cornea
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
França